March 10 (Reuters) – Gerresheimer on Tuesday again deferred the release of 2025 financial statements to June, citing a probe into its business deals, a delay that is now set to cost the German medical products maker its place on the Deutsche Boerse’s SDAX index.
The company said the delays were due to investigations by an external auditing firm into business transactions in 2024 and 2025, and the preparation of documents taking longer than expected.
The results release was originally due February 26.
Earlier on Tuesday, Germany’s financial watchdog BaFin said it has initiated an audit of Gerresheimer’s interim financial statements dated from December 1, 2024 to May 31, 2025.
The company said it would also delay the release of its first-quarter results, previously scheduled for April 16.
(Reporting by Gnaneshwar Rajan in Bengaluru; Editing by Shilpi Majumdar)
Comments